Cancer drug Iressa has a higher rate of a potentially fatal side effect then what was demonstrated in an earlier study, AstraZeneca said last week.
“A new 10-month study involving 3,322 lung cancer patients found 5.8 percent of them suffered interstitial pneumonia within eight weeks of starting treatment with Iressa, with a mortality rate of 2.3 […]